Last reviewed · How we verify
NCT06603506: PENDOR
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
trial testing tumour and blood samples in Endometrial Cancer in 16 participants. Currently enrolling.
15 October 2027
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 21 November 2024 |
| Primary completion | 15 October 2027 |
| Estimated completion | 15 October 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- tumour and blood samples
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.
Gall GL, Cherifi F, Divoux J, Florent R, et al · · 2025 · cited 2× · PMID 39934735 · DOI 10.1186/s12885-025-13590-6 -
Engineering the Human Endometrial-Embryo Interface: Breakthroughs in 3D Uterine Models.
Douglas JA, Higgins J, Wimalasiri DH, Winship AL, et al · · 2026 · PMID 41897319 · DOI 10.3390/biom16030383
Verify or expand the search:
- PubMed search for NCT06603506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06603506 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 26 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06603506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing